March 29, 2017 — In patients with a complete, persistent arterial blockage, medication alone was found to be equal to ...
MDBuyline analyst Tom Watson shares some of the most important trends in cardiac technology he saw at the 2017 American ...
Philips and the U.S. Food and Drug Administration (FDA) announced the company has initiated a recall of its HeartStart MRx Monitor/Defibrillator. The Class I recall is due to electrical and battery connection issues that may prevent the device from powering up, charging and delivering electrical shock therapy. The device may also unexpectedly stop pacing. A delay in delivering therapy could result in serious patient injury such as permanent organ damage, brain injury or death.
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
When used as a preventive measure during heart surgery, the heart failure drug levosimendan did not significantly reduce rates of death, heart attack, kidney dialysis or use of a mechanical assist device among patients at high risk for low cardiac output syndrome. These findings were part of a study presented at the American College of Cardiology’s 66th Annual Scientific Session, March 17-19 in Washington, D.C.
Young rabbits exposed to ultrasound during fetal development had weaker thighbones than unexposed rabbits, according to a study published in the Pertanika Journal of Science & Technology. While the finding applies to a relatively small group of test subjects, 142 young rabbits, it raises questions about the rising use of prenatal ultrasounds in women worldwide.
March 27, 2017 — Patients experiencing a major heart attack often have more than one clogged artery, but under current ...
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
Participants in Web-based lifestyle counseling reduced their systolic blood pressure by 10 mmHg, compared with a 6 mmHg reduction for those taking part in a web-based control intervention, a statistically significant difference, according to a new study. The research from this trial — the first randomized, double-blinded trial of an online behavioral intervention for high blood pressure — was presented at the American College of Cardiology’s 66th Annual Scientific Session, March 17-19 in Washington, D.C.
Using genetic testing to help personalize warfarin therapy given to patients undergoing elective orthopedic surgery appears to lower the risk of combined adverse events compared with clinically guided dosing, according to new research. Researchers said these findings could have implications for a broad population of patients starting warfarin therapy.
Michael Reardon, M.D., professor of cardiothoracic surgery at Houston Methodist DeBakey Heart and Vascular Center ...
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
March 24, 2017 — Facing the reality of not having enough votes to secure its passage, House leadership withdrew the ...
Safe implementation of new technologies and therapies accompany classic patient safety challenges on ECRI Institute's “2017 Top 10 Patient Safety Concerns for Healthcare Organizations.” The report highlights concerns from health information management, clinical decision support and new oral anticoagulants, to long-standing concerns like test result reporting and follow-up and unrecognized patient deterioration.
At the 2017 American College of Cardiology's Annual Scientific Session & Expo (ACC.17), Philips showcased a broad range of integrated, patient-centric solutions designed to address the prevention, diagnosis, minimally invasive treatment and chronic care at home of cardiac conditions.
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
Justin Davies, MBBS, of Imperial College London, and Matthias Götberg, M.D, Ph.D., of Skane University Hospital, detail ...
Bleeding complications did not increase for patients with acute coronary syndrome treated with rivaroxaban in addition to an antiplatelet medication compared with patients who received the standard treatment of aspirin plus an antiplatelet drug, according to new research. The research was presented at the American College of Cardiology’s 66th Annual Scientific Session, March 17-19 in Washington, D.C.
March 23, 2017 — Biotronik announced the European launch of the Edora series, its smallest series of pacemakers and ...